详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

A Prospective Study on Therapeutic Gain by Concurrent Chemoradiotherapy for Stage II-IVa Nasopharyngeal Carcinoma

96| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

出处：

DOI：

ISSN：

关键词： nasopharyngeal carcinoma radiotherapy concurrent chemotherapy sequential chemotherapy long-term survival

摘要：

The benefit achieved by concurrent chemoradiotherapy (CCR) and sequential chemoradiotherapy (SCR) vs radiotherapy (RT) alone for patients with stage II-IVa nasopharyngeal carcinoma (NPC) was compared. A total of 113 patients with stage II-IV a NPC were allotted into CCR group (n=38), SCR group (n=36) and RT alone group (n=39). All patients were irradiated with the same RT technique to >= 66 Gy at 2 Gy per fraction, conventional 5 fractions/week in all groups. The CCR group received concurrent chemotherapy of weekly cisplatin for 7 weeks, and the SCR group received neoadjuvant and (or) adjuvant chemotherapy. The results showed that the 3- and 5-year overall survival rate was significantly higher in CCR group than in RT alone group (92.16% vs 61.54%, 81.58% vs 51.28%, P<0.005). The median survival time was significantly longer in CCR group than in RT alone group (67.8 months vs 52.7 months, P<0.005). It was concluded that CCR could significantly improve overall survival rate, progression-free survival rate, and median survival time when compared with RT alone.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2010]版：

大类 | 4 区医学

小类 | 4 区生化与分子生物学

最新[2025]版：

无

JCR分区：

出版当年[2009]版：

Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

最新[2023]版：

无

影响因子： 0 最新[2023版] 0 最新五年平均 0.311 出版当年[2009版] 0 出版当年五年平均 0 出版前一年[2008版] 0.405 出版后一年[2010版]

第一作者：

第一作者单位： [1]Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]A Prospective Study on Therapeutic Gain by Concurrent Chemoradiotherapy for Stage II-IVa Nasopharyngeal Carcinoma [2]The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT [3]Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer [4]Postoperative sequential chemotherapy and radiotherapy for locally advanced gastric cancer [5]Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial [6]INDUCTION CHEMOTHERAPY PLUS CONCURRENT CHEMORADIOTHERAPY VERSUS CONCURRENT CHEMORADIOTHERAPY ALONE IN PATIENTS WITH LOCOREGIONALLY ADVANCED NASOPHARYNGEAL CARCINOMA: PRELIMINARY RESULTS OF A PHASE 3 MULTICENTRE RANDOMISED CONTROLLED TRIAL [7]The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis [8]Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial [9]Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial [10]鼻咽癌患者营养状态变化调查